LeMaitre Vascular, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 01, 2023 at 04:05 pm EDT
Share
LeMaitre Vascular, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 47.41 million compared to USD 39.03 million a year ago. Net income was USD 7.5 million compared to USD 5.46 million a year ago. Basic earnings per share from continuing operations was USD 0.34 compared to USD 0.25 a year ago. Diluted earnings per share from continuing operations was USD 0.33 compared to USD 0.25 a year ago.
For the nine months, sales was USD 144.6 million compared to USD 120.7 million a year ago. Net income was USD 21.64 million compared to USD 15.01 million a year ago. Basic earnings per share from continuing operations was USD 0.97 compared to USD 0.68 a year ago. Diluted earnings per share from continuing operations was USD 0.97 compared to USD 0.68 a year ago.
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Companyâs principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.